Suppr超能文献

用于原发性肿瘤术中近红外荧光成像的蛋白酶激活吲哚菁绿纳米探针。

Protease-activated indocyanine green nanoprobes for intraoperative NIR fluorescence imaging of primary tumors.

作者信息

Lew Benjamin, George Mebin, Blair Steven, Zhu Zhongmin, Liang Zuodong, Ludwig Jamie, Kim Celeste Y, Kim Kyekyoon Kevin, Gruev Viktor, Choi Hyungsoo

机构信息

Department of Electrical and Computer Engineering, University of Illinois Urbana IL 61801 USA

Division of Animal Resources, University of Illinois Urbana IL 61801 USA.

出版信息

Nanoscale Adv. 2022 Jul 1;4(19):4041-4050. doi: 10.1039/d2na00276k. eCollection 2022 Sep 27.

Abstract

Tumor-targeted fluorescent probes in the near-infrared spectrum can provide invaluable information about the location and extent of primary and metastatic tumors during intraoperative procedures to ensure no residual tumors are left in the patient's body. Even though the first fluorescence-guided surgery was performed more than 50 years ago, it is still not accepted as a standard of care in part due to the lack of efficient and non-toxic targeted probes approved by regulatory agencies around the world. Herein, we report protease-activated cationic gelatin nanoparticles encapsulating indocyanine green (ICG) for the detection of primary breast tumors in murine models with high tumor-to-background ratios. Upon intravenous administration, these nanoprobes remain optically silent due to the energy resonance transfer among the bound ICG molecules. As the nanoprobes extravasate and are exposed to the acidic tumor microenvironment, their positive surface charges increase, facilitating cellular uptake. The internalized nanoprobes are activated upon proteolytic degradation of gelatin to allow high contrast between the tumor and normal tissue. Since both gelatin and ICG are FDA-approved for intravenous administration, this activatable nanoprobe can lead to quick clinical adoption and improve the treatment of patients undergoing image-guided cancer surgery.

摘要

近红外光谱中的肿瘤靶向荧光探针能够在术中提供有关原发性和转移性肿瘤的位置及范围的宝贵信息,以确保患者体内无残留肿瘤。尽管首次荧光引导手术在50多年前就已开展,但它仍未被视为一种标准治疗方法,部分原因是缺乏全球监管机构批准的高效且无毒的靶向探针。在此,我们报告了包封吲哚菁绿(ICG)的蛋白酶激活阳离子明胶纳米颗粒,用于在小鼠模型中以高肿瘤与背景比率检测原发性乳腺肿瘤。静脉注射后,由于结合的ICG分子之间的能量共振转移,这些纳米探针保持光学沉默。随着纳米探针渗出并暴露于酸性肿瘤微环境中,其正表面电荷增加,促进细胞摄取。内化的纳米探针在明胶蛋白水解降解后被激活,从而使肿瘤与正常组织之间形成高对比度。由于明胶和ICG均已获得FDA批准用于静脉给药,这种可激活的纳米探针可迅速被临床采用,并改善接受图像引导癌症手术患者的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d56c/9514568/2fd8caa97708/d2na00276k-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验